Placebo Control

PDUFA V commitments signal a strong commitment to tolerance of open debate in the face of uncertainty. I can admit to a rather powerful la...

Ben Goldacre – whose Bad Pharma went on sale today – is fond of using a coin-toss-cheating analogy to describe the problem of "hidde...

I am in the process of writing up a review of this rather terrible Forbes piece on the FDA recall of one manufacturer's version of gen...

Updating my post from last month about the launch announcement for TransCelerate BioPharma , a nonprofit entity funded by 10 large pharmac...

It’s Gresham’s Law for clinical trial metrics: Bad data drives out good. Here are 4 steps you can take to fix it. Many years ago, when I ...

TransCelerate: Pharma's great kumbaya moment? Last week, 10 of the largest pharmaceutical companies caused quite a hullaballoo in t...

* for some value of "most" ** for some value of "too" [Note: this is a companion to a previous post, Clouding the Deba...

I am a bit delayed getting my latest post up.   I am writing up some thoughts on this recentstudy put out by ARCO, which suggests that ...

Pretty much everyone involved in patient recruitment for clinical trials seems to agree that "metrics" are, in some general sense,...

Following up on yesterday's post regarding a study of placebo-related information, it seems worthwhile to pause and expand on the diffe...